{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:53:20Z","timestamp":1790268800567,"version":"4.1.0"},"reference-count":118,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","cell.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Immunology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.it.2017.10.005","type":"journal-article","created":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T03:15:29Z","timestamp":1511925329000},"page":"151-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":114,"title":["Mast Cells as Drivers of Disease and Therapeutic Targets"],"prefix":"10.1016","volume":"39","author":[{"given":"Frank","family":"Siebenhaar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank A.","family":"Redegeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan C.","family":"Bischoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard F.","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.it.2017.10.005_bib0005","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.it.2017.04.001","article-title":"Rheostatic functions of mast cells in the control of innate and adaptive immune responses","volume":"38","author":"Frossi","year":"2017","journal-title":"Trends Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0010","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.it.2017.01.008","article-title":"Positive and negative signals in mast cell activation","volume":"38","author":"Bulfone-Paus","year":"2017","journal-title":"Trends Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejphar.2015.07.017","article-title":"Non-IgE mediated mast cell activation","volume":"778","author":"Yu","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.it.2017.10.005_bib0020","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000087644","article-title":"Using mast cell knock-in mice to analyze the roles of mast cells in allergic responses in vivo","volume":"87","author":"Tsai","year":"2005","journal-title":"Chem. Immunol. Allergy"},{"key":"10.1016\/j.it.2017.10.005_bib0025","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.4049\/jimmunol.171.8.4385","article-title":"Mast cells exert effects outside the central nervous system to influence experimental allergic encephalomyelitis disease course","volume":"171","author":"Tanzola","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0030","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.coi.2010.08.015","article-title":"Mast cell mediators in tolerance","volume":"22","author":"de Vries","year":"2010","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0035","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.immuni.2012.09.023","article-title":"Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor","volume":"38","author":"Zaiss","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.it.2017.10.005_bib0040","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1084\/jem.188.12.2343","article-title":"The c-kit ligand, stem cell factor, can enhance innate immunity through effects on mast cells","volume":"188","author":"Maurer","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.it.2017.10.005_bib0045","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature03085","article-title":"Mast cells promote homeostasis by limiting endothelin-1-induced toxicity","volume":"432","author":"Maurer","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.it.2017.10.005_bib0050","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1172\/JCI46139","article-title":"Mast cell chymase reduces the toxicity of Gila monster venom, scorpion venom, and vasoactive intestinal polypeptide in mice","volume":"121","author":"Akahoshi","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.it.2017.10.005_bib0055","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jaci.2015.08.005","article-title":"IgE antibodies, FcepsilonRIalpha, and IgE-mediated local anaphylaxis can limit snake venom toxicity","volume":"137","author":"Starkl","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0060","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1158\/2326-6066.CIR-13-0119","article-title":"Mast cells: potential positive and negative roles in tumor biology","volume":"1","author":"Marichal","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.it.2017.10.005_bib0065","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1126\/science.1128877","article-title":"Mast cells can enhance resistance to snake and honeybee venoms","volume":"313","author":"Metz","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.it.2017.10.005_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/all.12517","article-title":"The search for mast cell and basophil models \u2013 are we getting closer to pathophysiological relevance?","volume":"70","author":"Siebenhaar","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.it.2017.10.005_bib0075","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.immuni.2011.03.028","article-title":"Mast cells are key promoters of contact allergy that mediate the adjuvant effects of haptens","volume":"34","author":"Dudeck","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.it.2017.10.005_bib0080","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1038\/jid.2014.222","article-title":"Mast cells are key mediators of cathelicidin-initiated skin inflammation in rosacea","volume":"134","author":"Muto","year":"2014","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.it.2017.10.005_bib0085","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.immuni.2012.04.013","article-title":"Critical role for mast cells in interleukin-1beta-driven skin inflammation associated with an activating mutation in the nlrp3 protein","volume":"37","author":"Nakamura","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.it.2017.10.005_bib0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025538","article-title":"Requirement of interaction between mast cells and skin dendritic cells to establish contact hypersensitivity","volume":"6","author":"Otsuka","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.it.2017.10.005_bib0095","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.celrep.2013.12.029","article-title":"Critical role for mast cell Stat5 activity in skin inflammation","volume":"6","author":"Ando","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.it.2017.10.005_bib0100","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.ajpath.2015.02.005","article-title":"Mast cells are dispensable in a genetic mouse model of chronic dermatitis","volume":"185","author":"Sulcova","year":"2015","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.it.2017.10.005_bib0105","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/bjd.13857","article-title":"Mast-cell interleukin-1beta, neutrophil interleukin-17 and epidermal antimicrobial proteins in the neutrophilic urticarial dermatosis in Schnitzler\u2019s syndrome","volume":"173","author":"de Koning","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.it.2017.10.005_bib0110","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bbadis.2011.02.009","article-title":"New insights into the role of mast cells in autoimmunity: evidence for a common mechanism of action?","volume":"1822","author":"Walker","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.it.2017.10.005_bib0115","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jaci.2016.08.011","article-title":"Mast cells are associated with the onset and progression of celiac disease","volume":"139","author":"Frossi","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0120","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrcardio.2015.117","article-title":"Mast cells in human and experimental cardiometabolic diseases","volume":"12","author":"Shi","year":"2015","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.it.2017.10.005_bib0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037202","article-title":"Immunological and regenerative aspects of hepatic mast cells in liver allograft rejection and tolerance","volume":"7","author":"Nakano","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.it.2017.10.005_bib0130","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-1-4939-1568-2_7","article-title":"Mast cells in human health and disease","volume":"1220","author":"DeBruin","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.it.2017.10.005_bib0135","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1365-2133.2009.09516.x","article-title":"Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus","volume":"162","author":"Vieira Dos Santos","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.it.2017.10.005_bib0140","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1183\/13993003.00536-2015","article-title":"Allergen-induced airway responses","volume":"46","author":"Gauvreau","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.it.2017.10.005_bib0145","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1067\/mai.2000.110930","article-title":"Tear and conjunctival changes during the allergen-induced early- and late-phase responses","volume":"106","author":"Bacon","year":"2000","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0150","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/all.12006","article-title":"Colonoscopic allergen provocation test with rBet v 1 in patients with pollen-associated food allergy","volume":"67","author":"Pickert","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.it.2017.10.005_bib0155","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2133.2009.09434.x","article-title":"Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial","volume":"162","author":"Hartmann","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.it.2017.10.005_bib0160","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjd.14820","article-title":"Patients with chronic cold urticaria may benefit from doxycycline therapy","volume":"176","author":"Gorczyza","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.it.2017.10.005_bib0165","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.it.2017.10.005_bib0170","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/1523-1747.ep12471299","article-title":"In vitro functional reactivities of cutaneous mast cells from patients with mastocytosis","volume":"89","author":"Tharp","year":"1987","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.it.2017.10.005_bib0175","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.yexcr.2016.03.013","article-title":"The development of human mast cells. An historical reappraisal","volume":"342","author":"Ribatti","year":"2016","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.it.2017.10.005_bib0180","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/exd.13206","article-title":"Membrane-bound stem cell factor is the major but not only driver of fibroblast-induced murine skin mast cell differentiation","volume":"26","author":"Leist","year":"2017","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.it.2017.10.005_bib0185","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.molimm.2014.01.018","article-title":"Mast cell progenitors: origin, development and migration to tissues","volume":"63","author":"Dahlin","year":"2015","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0190","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jaci.2007.05.046","article-title":"H4 histamine receptor mediates optimal migration of mast cell precursors to CXCL12","volume":"120","author":"Godot","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0195","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.drudis.2014.05.007","article-title":"Histamine H4 receptor antagonists for the treatment of inflammatory disorders","volume":"19","author":"Liu","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.it.2017.10.005_bib0200","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.jaci.2016.05.046","article-title":"Pharmacologic inhibition of Notch signaling suppresses food antigen-induced mucosal mast cell hyperplasia","volume":"139","author":"Honjo","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0205","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jaci.2015.01.021","article-title":"TH9 cells are required for tissue mast cell accumulation during allergic inflammation","volume":"136","author":"Sehra","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0210","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10565-016-9379-0","article-title":"Upregulated expression of substance P (SP) and NK1R in eczema and SP-induced mast cell accumulation","volume":"33","author":"Zhan","year":"2017","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.it.2017.10.005_bib0215","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.4049\/jimmunol.144.5.1886","article-title":"The role of mast cell degranulation products in mast cell hyperplasia. I. Mechanism of action of nerve growth factor","volume":"144","author":"Marshall","year":"1990","journal-title":"J. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0220","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jaci.2011.11.009","article-title":"Endocannabinoids limit excessive mast cell maturation and activation in human skin","volume":"129","author":"Sugawara","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0225","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jaci.2013.01.002","article-title":"Cannabinoid receptor 1 controls human mucosal-type mast cell degranulation and maturation in situ","volume":"132","author":"Sugawara","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0230","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jaci.2013.02.042","article-title":"Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis","volume":"131","author":"Otani","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0235","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.iac.2014.01.012","article-title":"Treatment strategies in mastocytosis","volume":"34","author":"Siebenhaar","year":"2014","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"10.1016\/j.it.2017.10.005_bib0240","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2222.1989.tb02338.x","article-title":"Prolonged treatment with topical glucocorticoids results in an inhibition of the allergen-induced weal-and-flare response and a reduction in skin mast cell numbers and histamine content","volume":"19","author":"Pipkorn","year":"1989","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.it.2017.10.005_bib0245","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.it.2017.10.005_bib0250","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1182\/blood-2015-06-649525","article-title":"Cladribine for mastocytosis: benefits and risks","volume":"126","author":"Akin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.it.2017.10.005_bib0255","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrclinonc.2016.41","article-title":"Immunological off-target effects of imatinib","volume":"13","author":"Zitvogel","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.it.2017.10.005_bib0260","doi-asserted-by":"crossref","first-page":"68950","DOI":"10.18632\/oncotarget.10711","article-title":"Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature","volume":"8","author":"Alvarez-Twose","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.it.2017.10.005_bib0265","article-title":"Imatinib: a breakthrough of targeted therapy in cancer","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Chemother. Res. Pract."},{"key":"10.1016\/j.it.2017.10.005_bib0270","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.it.2017.10.005_bib0275","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood.V128.22.1965.1965","article-title":"The multi-kinase inhibitor DCC-2618 inhibits proliferation and survival of neoplastic mast cells and other cell types involved in systemic mastocytosis","volume":"128","author":"Schneeweiss","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.it.2017.10.005_bib0280","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11899-015-0280-3","article-title":"Tyrosine kinase inhibitors and therapeutic antibodies in advanced eosinophilic disorders and systemic mastocytosis","volume":"10","author":"Gotlib","year":"2015","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.it.2017.10.005_bib0285","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1158\/2159-8290.CD-NB2016-165","article-title":"BLU-285, DCC-2618 show activity against GIST","volume":"7","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.it.2017.10.005_bib0290","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3389\/fimmu.2012.00238","article-title":"Novel identified receptors on mast cells","volume":"3","author":"Migalovich-Sheikhet","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0295","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.pharmthera.2012.06.005","article-title":"Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions","volume":"135","author":"Kiwamoto","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.it.2017.10.005_bib0300","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejphar.2015.05.071","article-title":"Mast cell stabilisers","volume":"778","author":"Zhang","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.it.2017.10.005_bib0305","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jaci.2014.03.007","article-title":"Molecular targets on mast cells and basophils for novel therapies","volume":"134","author":"Harvima","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0310","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.pharmthera.2014.01.004","article-title":"Targeting mast cells in inflammatory diseases","volume":"142","author":"Reber","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.it.2017.10.005_bib0315","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.it.2017.10.005_bib0320","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2015.12.1342","article-title":"Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials","volume":"137","author":"Zhao","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0325","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.jaci.2014.02.005","article-title":"Accelerated dissociation of IgE-FcepsilonRI complexes by disruptive inhibitors actively desensitizes allergic effector cells","volume":"133","author":"Eggel","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0330","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/sji.12436","article-title":"Identification of Biological and pharmaceutical mast cell- and basophil-related targets","volume":"83","author":"Klein","year":"2016","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0335","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/bph.12038","article-title":"Characterization of AQX-1125, a small-molecule SHIP1 activator: part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo","volume":"168","author":"Stenton","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.it.2017.10.005_bib0340","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/cea.12370","article-title":"The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma","volume":"44","author":"Leaker","year":"2014","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.it.2017.10.005_bib0345","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jaci.2015.12.1313","article-title":"Randomized phase 1 study of the phosphatidylinositol 3-kinase delta inhibitor idelalisib in patients with allergic rhinitis","volume":"137","author":"Horak","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0350","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jaci.2012.07.014","article-title":"A specific sphingosine kinase 1 inhibitor attenuates airway hyperresponsiveness and inflammation in a mast cell-dependent murine model of allergic asthma","volume":"131","author":"Price","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0355","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/sj.bjp.0707002","article-title":"Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506","volume":"150","author":"Harrison","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.it.2017.10.005_bib0360","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1166\/jbn.2014.1807","article-title":"Highly specific targeting of human leukocytes using gold nanoparticle-based biologically active conjugates","volume":"10","author":"Gibbs","year":"2014","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.it.2017.10.005_bib0365","doi-asserted-by":"crossref","first-page":"665","DOI":"10.4049\/jimmunol.179.1.665","article-title":"Fullerene nanomaterials inhibit the allergic response","volume":"179","author":"Ryan","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0370","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nri3690","article-title":"Mast cell secretory granules: armed for battle","volume":"14","author":"Wernersson","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0375","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3389\/fimmu.2014.00569","article-title":"Mast cell mediators: their differential release and the secretory pathways involved","volume":"5","author":"Moon","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0380","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejphar.2015.04.045","article-title":"Mast cell proteases as pharmacological targets","volume":"778","author":"Caughey","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.it.2017.10.005_bib0385","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/1440-1681.12549","article-title":"Improvement of cardiovascular remodelling by chymase inhibitor","volume":"43","author":"Takai","year":"2016","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.it.2017.10.005_bib0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/all.12531","article-title":"Update on rupatadine in the management of allergic disorders","volume":"70","author":"Mullol","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.it.2017.10.005_bib0395","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1016\/j.bmcl.2016.11.022","article-title":"The discovery of quinoline based single-ligand human H1 and H3 receptor antagonists","volume":"26","author":"Procopiou","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.it.2017.10.005_bib0400","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bph.12138","article-title":"Twenty-first century mast cell stabilizers","volume":"170","author":"Finn","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.it.2017.10.005_bib0405","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nrd3871","article-title":"Protein kinase C, an elusive therapeutic target?","volume":"11","author":"Mochly-Rosen","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.it.2017.10.005_bib0410","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1756-8722-6-59","article-title":"Ibrutinib and novel BTK inhibitors in clinical development","volume":"6","author":"Akinleye","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.it.2017.10.005_bib0415","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0420","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1398-9995.2011.02546.x","article-title":"Inhibition of ongoing allergic reactions using a novel anti-IgE DARPin-Fc fusion protein","volume":"66","author":"Eggel","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.it.2017.10.005_bib0425","doi-asserted-by":"crossref","first-page":"14115","DOI":"10.1073\/pnas.1608520113","article-title":"Exon skipping of FcepsilonRIbeta eliminates expression of the high-affinity IgE receptor in mast cells with therapeutic potential for allergy","volume":"113","author":"Cruse","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.it.2017.10.005_bib0430","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1517\/13543784.2013.839658","article-title":"Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs","volume":"23","author":"Norman","year":"2014","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.it.2017.10.005_bib0435","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00535-016-1283-0","article-title":"Emerging biologics in inflammatory bowel disease","volume":"52","author":"Chan","year":"2017","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.it.2017.10.005_bib0440","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00296-016-3436-0","article-title":"Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies","volume":"36","author":"Elyoussfi","year":"2016","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.it.2017.10.005_bib0445","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9259646","article-title":"Biologics for targeting inflammatory cytokines, clinical uses, and limitations","volume":"2016","author":"Rider","year":"2016","journal-title":"Int. J. Cell Biol."},{"key":"10.1016\/j.it.2017.10.005_bib0450","first-page":"243","article-title":"Advances in the development of new biologics in inflammatory bowel disease","volume":"29","author":"Ungar","year":"2016","journal-title":"Ann. Gastroenterol."},{"key":"10.1016\/j.it.2017.10.005_bib0455","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1074\/jbc.M501302200","article-title":"A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti-inflammatory activity in vivo","volume":"280","author":"de Garavilla","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.it.2017.10.005_bib0460","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1164\/rccm.200904-0627OC","article-title":"Dual inhibition of cathepsin G and chymase is effective in animal models of pulmonary inflammation","volume":"181","author":"Maryanoff","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.it.2017.10.005_bib0465","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1034\/j.1600-065X.2001.1800101.x","article-title":"The role of complement in inflammation and adaptive immunity","volume":"180","author":"Barrington","year":"2001","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.it.2017.10.005_bib0470","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1172\/JCI85538","article-title":"Different activation signals induce distinct mast cell degranulation strategies","volume":"126","author":"Gaudenzio","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.it.2017.10.005_bib0475","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ctrv.2015.09.005","article-title":"Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: rolapitant and NEPA (netupitant\/palonosetron)","volume":"41","author":"Rojas","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.it.2017.10.005_bib0480","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4172\/2476-1966.1000115","article-title":"Mas-related G protein coupled receptor-X2: a potential new target for modulating mast cell-mediated allergic and inflammatory diseases","volume":"1","author":"Ali","year":"2016","journal-title":"J. Immunobiol."},{"key":"10.1016\/j.it.2017.10.005_bib0485","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature14022","article-title":"Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions","volume":"519","author":"McNeil","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.it.2017.10.005_bib0490","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jaci.2016.04.051","article-title":"Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases","volume":"138","author":"Subramanian","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0495","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3389\/fphar.2015.00065","article-title":"The histamine H4 receptor: from orphan to the clinic","volume":"6","author":"Thurmond","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.it.2017.10.005_bib0500","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.4049\/jimmunol.1003383","article-title":"Mast cells as sensors of cell injury through IL-33 recognition","volume":"186","author":"Enoksson","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0505","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/j.1398-9995.2012.02859.x","article-title":"Interleukin-33 amplifies IgE synthesis and triggers mast cell degranulation via interleukin-4 in naive mice","volume":"67","author":"Komai-Koma","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.it.2017.10.005_bib0510","first-page":"575","article-title":"Interleukin-33 promotes the proliferation of mouse mast cells through ST2\/MyD88 and p38 MAPK-dependent and Kit-independent pathways","volume":"28","author":"Saluja","year":"2014","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.it.2017.10.005_bib0515","first-page":"177","article-title":"Neuropeptide NGF mediates neuro-immune response and inflammation through mast cell activation","volume":"28","author":"Kritas","year":"2014","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.it.2017.10.005_bib0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/imm.12717","article-title":"Nerve growth factor: a neuroimmune crosstalk mediator for all seasons","volume":"151","author":"Skaper","year":"2017","journal-title":"Immunology"},{"key":"10.1016\/j.it.2017.10.005_bib0525","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/nm722","article-title":"Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses","volume":"8","author":"Redegeld","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.it.2017.10.005_bib0530","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jaci.2010.02.039","article-title":"Contribution of IgE and immunoglobulin free light chain in the allergic reaction to cow\u2019s milk proteins","volume":"125","author":"Schouten","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0535","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1365-2222.2007.02655.x","article-title":"Topical application of F991, an immunoglobulin free light chain antagonist, prevents development of contact sensitivity in mice","volume":"37","author":"van Houwelingen","year":"2007","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.it.2017.10.005_bib0540","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fcell.2016.00043","article-title":"Tetraspanins and transmembrane adaptor proteins as plasma membrane organizers-mast cell case","volume":"4","author":"Halova","year":"2016","journal-title":"Front. Cell Dev. Biol"},{"key":"10.1016\/j.it.2017.10.005_bib0545","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.4049\/jimmunol.1202323","article-title":"The tetraspanin CD63 is required for efficient IgE-mediated mast cell degranulation and anaphylaxis","volume":"191","author":"Kraft","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.it.2017.10.005_bib0550","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/glycob\/cww024","article-title":"\u201cSiglec\u201dting the allergic response for therapeutic targeting","volume":"26","author":"Bochner","year":"2016","journal-title":"Glycobiology"},{"key":"10.1016\/j.it.2017.10.005_bib0555","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jaci.2016.02.027","article-title":"Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses","volume":"138","author":"Gauvreau","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"issue":"7","key":"10.1016\/j.it.2017.10.005_bib0560","first-page":"1","article-title":"Looking forward to new targeted treatments for chronic spontaneous urticaria, Clin. Transl","volume":"10","author":"Kocat\u00fcrk","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.it.2017.10.005_bib0565","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0140-6736(16)31403-9","article-title":"Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study","volume":"389","author":"Lortholary","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.it.2017.10.005_bib0570","first-page":"9","article-title":"A precision therapy against cancers driven by KIT\/PDGFRA mutations","author":"Evans","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.it.2017.10.005_bib0575","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.it.2017.10.005_bib0580","doi-asserted-by":"crossref","first-page":"68950","DOI":"10.18632\/oncotarget.10711","article-title":"Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature","volume":"8","author":"Alvarez-Twose","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.it.2017.10.005_bib0585","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1007\/s00432-015-1988-0","article-title":"Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study","volume":"141","author":"Hochhaus","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.it.2017.10.005_bib0590","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1158\/1535-7163.MCT-13-0397","article-title":"Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing \u03b2-catenin signaling","volume":"13","author":"Jin","year":"2014","journal-title":"Mol. Cancer Ther."}],"container-title":["Trends in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471490617302089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471490617302089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T09:25:43Z","timestamp":1693301143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471490617302089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":118,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1471490617302089"],"URL":"https:\/\/doi.org\/10.1016\/j.it.2017.10.005","relation":{},"ISSN":["1471-4906"],"issn-type":[{"value":"1471-4906","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mast Cells as Drivers of Disease and Therapeutic Targets","name":"articletitle","label":"Article Title"},{"value":"Trends in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.it.2017.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}